Table 2 Baseline subject characteristics
Demographic | Treatment group (sirolimus + aflibercept) (N = 10) | Control group (aflibercept monotherapy) (N = 10) | p-value | ||
|---|---|---|---|---|---|
Mean | SD | Mean | SD | ||
Age at baseline (years) | 80.8 | 7.2 | 78.4 | 9.7 | 0.54 |
Intraocular pressure (mm Hg) | 16.3 | 2.9 | 14.3 | 2.0 | 0.09 |
Duration of exudative AMD (months) | 64.2 | 26.1 | 67.7 | 56.4 | 0.86 |
Previous intravitreal anti-VEGF injections (# of shots) | 43.0 | 18.1 | 34.1 | 21.7 | 0.33 |
Baseline visual acuity (ETDRS letters) | 62.6 | 9.0 | 61.0 | 14.1 | 0.77 |
Baseline central subfield thickness (μm) | 444.2 | 114.8 | 507.9 | 118.0 | 0.24 |
Baseline subretinal volume (mm3) | 11.0 | 26.8 | 9.8 | 14.4 | 0.91 |
Baseline intraretinal volume (mm3) | 0.4 | 1.3 | 1.3 | 3.7 | 0.52 |
Central 1 mm foveal volume (mm3) | 8.5 | 0.8 | 9.3 | 1.0 | 0.11 |
Weeks since last anti-VEGF treatment | 4.8 | 0.6 | 6.3 | 2.5 | 0.10 |